EW
55
-2
NWSA
64
4
COF
65
2
IVZ
55
-8
QCOM
46
2
AME
66
4
DE
48
5
KSS
58
-2
TROW
58
5
WM
56
3
VIX
22
-2
EQR
50
-3
UNH
37
4
HOG
45
3
APD
55
3
GILD
52
2
MA
48
2
KMB
45
-3
SHW
59
3
SYY
53
-3
EW
55
-2
NWSA
64
4
COF
65
2
IVZ
55
-8
QCOM
46
2
AME
66
4
DE
48
5
KSS
58
-2
TROW
58
5
WM
56
3
VIX
22
-2
EQR
50
-3
UNH
37
4
HOG
45
3
APD
55
3
GILD
52
2
MA
48
2
KMB
45
-3
SHW
59
3
SYY
53
-3
Financhill
Back

Capricor Therapeutics, Inc. 10K Form

Buy
61

CAPR
Capricor Therapeutics, Inc.

Last Price:
$25.42
Seasonality Move:
25.31%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive CAPR News And Ratings

See the #1 stock for the next 7 days that we like better than CAPR

CAPR Financial Statistics

Sales & Book Value

Annual Sales: $22.3M
Cash Flow: $-23.7M
Price / Cash Flow: 0
Annual Sales: $1.83
Price / Book: 16.33

Profitability

EPS (TTM): -1.79880
Net Income (TTM): $-82M
Gross Margin: $20.8M
Return on Equity: -77.32%
Return on Assets: -60.54%

Capricor Therapeutics, Inc. Earnings Forecast

Key Capricor Therapeutics, Inc. Financial Ratios

  • The Gross Profit Margin over the past 10 years for CAPR is 93.60%.
  • The Selling, General & Administrative Expenses for CAPR have been equal to 66.76% of Gross Profit Margin.
  • The Research & Development expenses have been 220.90% of Revenue.
  • The Net Earning history of CAPR is -181.71% of Total Revenues.
  • Per Share Earnings over the last 26 years have been positive in 12 years.

Capricor Therapeutics, Inc. Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: CAPR
CUSIP: 14070B
Website: capricor.com

Debt

Debt-to-Equity Ratio: 0.21
Current Ratio: 3.59
Quick Ratio: 3.5

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 81.29

CAPR Technical Analysis vs Fundamental Analysis

Buy
61
Capricor Therapeutics, Inc. (CAPR) is a Buy

Is Capricor Therapeutics, Inc. a Buy or a Sell?